Se proyecta que el mercado mundial de pruebas de susceptibilidad a los antimicrobianos alcance los 5.020 millones de dólares en 2029, desde los 3.100 millones de dólares en 2022, con una CAGR del 5,5 % entre 2023 y 2029.
La prueba de susceptibilidad a los antimicrobianos es una prueba de laboratorio que utilizan los científicos de laboratorio y los tecnólogos médicos cualificados para determinar si el régimen antimicrobiano de un paciente es eficaz. El objetivo básico de la prueba de susceptibilidad a los antimicrobianos es determinar si los antibióticos funcionarán o no. Para garantizar que los resultados se puedan repetir, estas pruebas se llevan a cabo en condiciones controladas. Los resultados de esta prueba ayudan a los médicos a elegir el antibiótico óptimo para el paciente. Se realizan pruebas periódicas de susceptibilidad a los antibióticos para garantizar que se utilicen de forma eficaz. Determina las concentraciones más bajas de medicamentos antimicrobianos nuevos o existentes que impiden el crecimiento constante y detectable de la bacteria en investigación en determinadas circunstancias de prueba. Implica encontrar resistencia a los medicamentos en algunas de las enfermedades más comunes, así como determinar la susceptibilidad de los tratamientos preferidos para determinadas infecciones.
| ATRIBUTO | DETALLES |
| Periodo de estudio | 2022-2029 |
| Año base | 2022 |
| Año estimado | 2023 |
| Año pronosticado | 2023-2029 |
| Periodo histórico | 2018-2021 |
| Unidad | Valor (miles de millones de USD) |
| Segmentación | Por producto, por método, por tipo, por aplicación, por usuario final, por región. |
| Por producto |
|
| Por método |
|
| Por tipo |
|
| Por aplicación |
|
| By Region |
|
The development of a new broad spectrum of antibacterial medications is required as the prevalence of infectious diseases rises. Governments all over the world are investing extensively in research and development for antimicrobial susceptibility test kits that generate faster results, and private firms are doing the same, which is projected to drive the antimicrobial susceptibility test market forward. Rapid test methods are emerging as a result of technological advancements in medical research, leading to the overall growth of the antimicrobial susceptibility test market over the forecast period.
This lowers the cost of antibacterial medications for pharmaceutical corporations. This lack of return on investment is hampering the worldwide market's expansion. Antimicrobial research and development, on the other hand, takes longer and necessitates more resources and specialised methodologies. In addition, an unfavorable reimbursement scenario and a low return on investment are impeding the growth of the Antimicrobial Susceptibility Test Market. On the other hand, the high cost of these systems is a key barrier to their widespread adoption by end-users, particularly small-budget organisations.
Antimicrobial susceptibility test kits are in high demand due to infectious organisms such as haemophilus influenzae, neisseria meningitides, streptococcus pneumoniae, shigella, vibrio cholerae, neisseria gonorrhoeae, and salmonella serotype typhi. The automated antimicrobial susceptibility test devices come with a variety of modern features and functions, and they're reasonably priced. When using automated Antimicrobial Susceptibility Test techniques, the incubation and detection times are cut in half. Antimicrobial medications, unlike other therapies for chronic illnesses that are used for the remainder of the patient's life, are only used for a brief time to cure the patients.
The antimicrobial susceptibility testing market size had crossed USD 3.10 Billion in 2020 and will observe a CAGR of more than 5.5% up to 2029 driven by the rising incidence of infectious diseases coupled with epidemic & pandemic events.
The upcoming trend in antimicrobial susceptibility testing market is awareness initiatives for antimicrobial resistance and its control is an opportunity for market growth.
The global antimicrobial susceptibility testing market registered a CAGR of 5.5% from 2022 to 2029. The method segment was the highest revenue contributor to the market.
Key players profiled in the report include BioMérieux, BD, Danaher, Thermo Fisher, Bio-Rad, Hi-Media, MERLIN, Liofilchem, Accelerate, and Alifax.
Clinical diagnostics segment is dominating the antimicrobial susceptibility testing market.
North America is the largest regional markets with 48% of share increased R&D to develop novel automated AST systems, rising prevalence of infectious diseases, safety concerns, and technological developments in antimicrobial susceptibility products.
The antimicrobial susceptibility test market is divided into automated laboratory instruments, susceptibility testing disks, manual antimicrobial susceptibility test products, MIC strips, susceptibility plates, culture and growth media, consumables based on products. Manual susceptibility testing products have dominated the antimicrobial susceptibility test market. The market is expected to grow as antimicrobial resistance develops, new products are released, and susceptibility testing equipment gain traction in emerging markets.
The market is divided into dilution, disk diffusion, ETEST, automated antimicrobial susceptibility test, genotypic method based on method. Among these approaches, the automated antimicrobial susceptibility test equipment sector had the biggest market share. The majority of the segment's revenue comes from its speed, precision, and capacity to deliver qualitative and quantitative susceptibility data. In addition, the segment's expansion is being fueled by technological advancements and increased R&D efforts by key rivals to provide innovative solutions to the market.
The market is divided into antibacterial testing, antifungal testing, and ant parasitic testing based on type. Among these, antibacterial susceptibility testing has the largest proportion of the market. The bulk of cases in this group are due to the abuse of broad-spectrum antibiotics and the emergence of multidrug resistance. Drug resistance develops in microorganisms as a result of the overuse of broad-spectrum antibiotics, prompting the need for better drug screening.
The market is divided into clinical diagnostics, drug discovery and development, epidemiology based on application. The clinical diagnostics segment commanded the most market share. The rising prevalence of infectious diseases, the rising incidence of HAIs, the large target patient population base (especially in emerging countries), the growing procedural volume of clinical diagnostic tests, the growing emphasis on effective and early disease diagnosis across major markets, and the introduction of various technologically advanced susceptibility testing products all contribute to this segment's large share.
The market is divided into diagnostic centers and hospitals, pharmaceutical and biotechnology companies, contract research organizations (CROS), research and academic institutes based on end user. Antifungal test procedure done in diagnostic laboratories and hospital, and also increase in the number of hospitals in significant market. Advances in healthcare infrastructure are expected to have an impact on the antibiotic susceptibility testing sector. The installation and use of more advanced, efficient, and sophisticated antibiotic susceptibility testing equipment and procedures at healthcare facilities all over the world has been made possible by government investment on healthcare.
[caption id="attachment_12596" align="aligncenter" width="680"]
The major players operating in the global antimicrobial susceptibility test industry include BioMérieux, BD, Danaher, Thermo Fisher, Bio-Rad, Hi-Media, MERLIN, Liofilchem, Accelerate, and Alifax. The presence of established industry players and is characterized by mergers and acquisitions, joint ventures, capacity expansions, substantial distribution, and branding decisions to improve market share and regional presence. Also, they are involved in continuous R&D activities to develop new products as well as are focused on expanding the product portfolio. This is expected to intensify competition and pose a potential threat to the new players entering the market.
Geographically, the antimicrobial susceptibility test market is segmented into North America, South America, Europe, APAC and MEA.
North America is expected to hold the largest share of the global antimicrobial susceptibility test market. The key drivers driving market growth in North America include increased R&D to develop novel automated AST systems, rising prevalence of infectious diseases, safety concerns, and technological developments in antimicrobial susceptibility products. Furthermore, most of the world's leading firms, including as Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, and Bruker Corporation, are located in the region or have a significant presence there. Others have concentrated on growth in order to broaden their reach and skills. Another important factor contributing to the market's rapid expansion is this.
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.